

Pharmaceutical
Multinationals

CHAPTER 3

Re-
"Investment
Is Even Bigger

Knowledge
+ Money

The Pharmaceutical Investment Business With the AIDS Epidemic

ASPEN

THE SCIENTIFIC FACTS ABOUT PHARMACEUTICAL AIDS DRUGS

The “TAC” and the “South African Medical Association” represent to the High Court that ARV drugs are a scientifically proven therapy to treat HIV infection and AIDS. These statements are false.

Witness after witness in this Application make representations to the effect that ARV drugs prevent the development of AIDS, increase survival time, and can potentially even cure AIDS. All these statements are equally false.

The assertions that ARVs can prevent the development of AIDS in HIV-infected patients or even cure AIDS is so provably false that none of the pharmaceutical companies producing ARV drugs are allowed or even dare to make such unsubstantiated claims.

It takes organisations like the “TAC” and the “South African Medical Association” to make such unproven claims. The only explanation for such irresponsible action is that the SAMA functionaries and the TAC until now essentially ignored the risk of product liability lawsuits from patients harmed by taking ARVs, which the manufacturers of these drugs cannot.

Remedy for such irresponsible action can only come if new legislation is passed that not only binds the manufacturers of drugs, but also anyone promoting their merchandise to be held legally responsible for any claims made, both to patients and publicly.

Because of the objective scientific facts about ARV drugs, namely a). the high toxicity of these drugs, and b). the inability of these drugs to prevent or cure neither HIV infections nor the development of AIDS, there exists an objective interest on behalf of the pharmaceutical companies manufacturing ARVs to promote these controversial drugs with the help of other organisations.



The TAC organises rented crowds for the drug industry: In this rally, in 2006, the TAC pushes for the registration of yet another toxic ARV drug unable to cure either HIV or AIDS. The primary beneficiaries of this ARV promotion campaign are not the people of South Africa, but the ARV-producing drug companies.

In light of the fact that both Applicants, the “TAC” and the “South African Medical Association”, are heavily involved in promoting ARV drugs, their statements have to be particularly scrutinised as to their scientific accuracy and their credibility.

In the context of this litigation it must be avoided at all costs that judges are misled by deceptive representations of ARV-promoting organisations – such as the SAMA functionaries and the TAC – in making rulings on the therapeutic value of ARV drugs which not even the manufacturers of these drugs can scientifically substantiate or are allowed to make.

This is particularly important since once before the “TAC” has used this ruse to have a South African Court make a ruling – entirely outside the scientific facts of the ARV manufacturers – based sole-

ly on the “pseudo expertise” of ARV promoting organisations and individuals. That highly publicised case had far-reaching implications for the people of South Africa, for it forced the Government of South Africa to roll out ARVs without any proven efficacy to treat HIV or AIDS to tens of thousands of South African people.

In the current Application the ARV promoting “TAC” is being officially joined by the board of the “South African Medical Association” in trying to use this ruse a second time in a South African Court by – once again – representing ARVs in a false, deceptive and malicious manner as the only scientifically proven method to prevent and treat and even cure AIDS.

In light of the necessity not to let any “pseudo-scientific” opinions by organisations promoting ARVs affect the fact finding during this litigation it is important to review the official statements made by the manufacturers of ARV drugs about their products. Following are just a few examples taken from the official product information of the manufacturers:

No Cure For HIV or AIDS!


- **NEVIRAPINE (“Viramune”)**
Manufacturer: Boehringer-Ingelheim (Germany/USA)

“VIRAMUNE is not a cure for HIV-1 infection; patients may continue to experience illnesses associated with advanced HIV-1 infection, including opportunistic infections. Patients should be advised to remain under the care of a physician when using VIRAMUNE.”*

No Cure For HIV or AIDS!

- **TIPRANAVIR (“Aptivus”)**
Manufacturer Boehringer-Ingelheim (Germany/USA)

“Patients should be informed that APTIVUS is not a cure for HIV-1 infection and that they may continue to develop opportunistic



“VIRAMUNE is not a cure for HIV-1 infection; patients may continue to experience illnesses associated with advanced HIV-1 infection, including opportunistic infections.”

Original Product Information for Nevirapine (“Viramune”)

There is no scientific evidence that any of the ARVs currently sold can cure either HIV or AIDS. Therefore, the manufacturers of ARV drugs around the world are required by law to warn patients: “This product is not a cure for HIV infection.”

infections and other complications associated with HIV disease. The long-term effects of APTIVUS are unknown at this time.”*

No Cure For HIV or AIDS!

- **ZIDOVUDINE (“Retrovir”)**
Manufacturer: GlaxoSmithKline (UK)

“RETROVIR is not a cure for HIV infection, and patients may continue to acquire illnesses associated with HIV infection, including opportunistic infections. Therefore, patients should be advised to seek medical care for any significant change in their health status.”*

No Cure For HIV or AIDS!

- **LAMIVUDINE + ZIDOVUDINE (“Combivir”)**
Manufacturer: GlaxoSmithKline (UK)

“COMBIVIR is not a cure for HIV infection and patients may continue to experience illnesses associated with HIV infection, including opportunistic infections. Patients should be advised that the use of COMBIVIR has not been shown to reduce the risk of transmission of HIV to others through sexual contact or blood contamination.”*

No Cure For HIV or AIDS!

- **ABACAVIR (“Ziagen”)**
Manufacturer: GlaxoSmithKline (UK)

“ZIAGEN is not a cure for HIV infection and patients may continue to experience illnesses associated with HIV infection, including opportunistic infections. Patients should remain under the care of a physician when using ZIAGEN. Patients should be advised that the use of ZIAGEN has not been shown to reduce the risk of transmission of HIV to others through sexual contact or blood contamination.”*

No Cure For HIV or AIDS!

- **ABACAVIR + LAMIVUDINE (“Kivexa/Epzicom[US]”)**
Manufacturer: GlaxoSmithKline (UK)

“EPZICOM is not a cure for HIV infection and patients may continue to experience illnesses associated with HIV infection, including opportunistic infections. Patients should remain under the care of a physician when using EPZICOM. Advise patients that the use of EPZICOM has not been shown to reduce the risk of transmission of HIV to others through sexual contact or blood contamination.”*



**“RETROVIR is
not a cure
for HIV-1 infection**
and patients may
continue to acquire
illnesses associated
with HIV infection,
including opportunistic
infections.”

Original Product
Information for
Zidovudine (“Retrovir”)

No Cure For HIV or AIDS!

- **FOSAMPRENAVIR (“Telzir/Lexiva[US]”)**
Manufacturer: GlaxoSmithKline (UK)

“Patients should be informed that LEXIVA is not a cure for HIV infection and that they may continue to develop opportunistic infections and other complications associated with HIV disease. The long-term effects of LEXIVA are unknown at this time. Patients should be told that there are currently no data demonstrating that therapy with LEXIVA can reduce the risk of transmitting HIV to others.”*

No Cure For HIV or AIDS!

- **ENFUVIRTIDE (“Fuzeon”)**
Manufacturer: Roche (Switzerland)

“FUZEON is not a cure for HIV infection or AIDS. FUZEON does not prevent the transmission of HIV. People taking FUZEON may still get opportunistic infections or other conditions that can happen with HIV infection.”*

No Cure For HIV or AIDS!

- **SAQUINAVIR (“Invirase”)**
Manufacturer: Roche (Switzerland)

“Patients should be informed that INVIRASE is not a cure for HIV infection and that they may continue to acquire illnesses associated with advanced HIV infection, including opportunistic infections.”*

No Cure For HIV or AIDS!

- **NELFINAVIR (“Viracept”)**
Manufacturer: Pfizer (USA) / Roche (Switzerland)

“VIRACEPT is not a cure for HIV infection or AIDS. People taking VIRACEPT may still develop opportunistic infections or other conditions associated with HIV infection. Some of these conditions are pneumonia, herpes virus infections, Mycobacterium avium complex (MAC) infections, and Kaposi’s sarcoma.”*

No Cure For HIV or AIDS!

- **DELAVIDINE (“Rescriptor”)**
Manufacturer: Pfizer Inc. (USA)

“Patients should be informed that RESCRIPTOR is not a cure for HIV-1 infection and that they may continue to acquire illnesses



“Patients should be informed that RESCRIPTOR is not a cure for HIV-1 infection and that they may continue to acquire illnesses associated with HIV-1 infection, including opportunistic infections.”

Original Product Information for Delavirdine (“Rescriptor”)

associated with HIV-1 infection, including opportunistic infections. Treatment with RESCRIPTOR has not been shown to reduce the incidence or frequency of such illnesses, and patients should be advised to remain under the care of a physician when using RESCRIPTOR. Patients should be advised that the use of RESCRIPTOR has not been shown to reduce the risk of transmission of HIV-1.”*

No Cure For HIV or AIDS!

- **LOPINAVIR + RITONAVIR (“Kaletra”)**
Manufacturer: Abbott Pharmaceuticals (USA)

“Patients should be informed that KALETRA is not a cure for HIV infection and that they may continue to develop opportunistic infections and other complications associated with HIV disease. The long-term effects of KALETRA are unknown at this time.”*

No Cure For HIV or AIDS!

- **RITONAVIR (“Norvir”)**
Manufacturer: Abbott Pharmaceuticals (USA)

“Patients should be informed that NORVIR is not a cure for HIV infection and that they may continue to acquire illnesses associated with advanced HIV infection, including opportunistic infections. Patients should be told that the long-term effects of NORVIR are unknown at this time.”*

No Cure For HIV or AIDS!

- **ATAZANAVIR (“Reyataz”)**
Manufacturer: Abbott Pharmaceuticals (USA)

“Patients should be informed that REYATAZ is not a cure for HIV infection and that they may continue to develop opportunistic infections and other complications associated with HIV disease. Patients should be told that there are currently no data demonstrating that therapy with REYATAZ can reduce the risk of transmitting HIV to others through sexual contact.”*

No Cure For HIV or AIDS!

- **EFIVARENZ (“Sustiva”)**
Manufacturer: Abbott Pharmaceuticals (USA)

“Patients should be informed that SUSTIVA is not a cure for HIV-1 infection and that they may continue to develop opportunistic infections and other complications associated with HIV-1 disease. Patients should be told that there are currently no data demonstrating that SUSTIVA therapy can reduce the risk of transmitting HIV to others through sexual contact or blood contamination.”*

No Cure For HIV or AIDS!

- **EFIVARENZ + EMTRICITABINE + TENOFOVIR (“Atripla”)**
Manufacturer: Bristol-Meyers Squibb

“ATRIPLA is not a cure for HIV infection and patients may continue to experience illnesses associated with HIV infection, including opportunistic infections. Patients should remain under the care of a physician when using ATRIPLA.”*

In light of these factual statements about the inability of ARVs to prevent or cure HIV or AIDS by the pharmaceutical companies who researched, developed, patented and market these products globally it is evident that the “TAC” and the “South African Medical Association” build their entire Application on an outright lie: the non-existing ability of ARVs to prevent or treat HIV or AIDS.

In light of the sobering information about AIDS drugs provided by those companies that developed these drugs it is inexcusable that a South African company - that was not involved in the development of these drugs but merely licenses them - tries to market toxic ARV drugs with the misleading promise that the ARV drugs may “improve your condition.” The following product information statements of “Aspen Pharmacare Pty Ltd.” about its leading ARV drugs “Nevirapine” and “Staduvine” have no scientific basis and are deliberately misleading the public:

No Cure For HIV or AIDS!

- **ASPEN NEVIRAPINE**
Manufacturer: Aspen Pharmacare Pty. Ltd.

“Aspen Nevirapine 200 mg may improve your condition, but it is not a cure for your HIV infection. HIV infection is a disease spread by contact with blood or sexual contact with an infected individual. Treatment with Aspen Nevirapine 200 mg has not been shown to reduce the risk of passing HIV infection on to others by sexual contact or by blood transfer.”*

No Cure For HIV or AIDS!

- **ASPEN ZIDOVUDINE**
Manufacturer: Aspen Pharmacare Ltd. Pty.

“Aspen Zidovudine 300 mg may improve your condition, but it is not a cure for your HIV infection. HIV infection is a disease spread by contact with blood or sexual contact with an infected individual. Treatment with Aspen Zidovudine 300 mg has not been shown to reduce the risk of passing HIV infection on to others by sexual contact or by blood transfer. Therefore, you must continue to take appropriate precautions to avoid giving the virus to others.”*

This deceptive labelling of “Aspen’s” ARV products is a fraud on the public. Without having been involved in the development of these ARV drugs, “Aspen” makes false and deceptive health claims about the possible efficacy of ARVs, that none of the pharmaceutical companies that actually developed them is allowed to make. Thus, there is an immediate need for the respective government authorities to intervene and to hold “Aspen” responsible for violating the “Medicines Control Act” and other South African laws. This intervention is particularly important, since “Aspen Pharmacare Pty. Ltd.” is not only promoting its ARVs to thousands of people in South Africa, but also exports them to other African countries with these fraudulent claims.

In summary, the comprehensive list of statements by the pharmaceutical companies that actually developed these ARV drugs unequivocally documents that none of these drugs has been proven to prevent or cure HIV or AIDS and none of these drugs are allowed to be marketed anywhere in the world with such claims.




The fact that none of the ARV products currently marketed in South Africa and beyond can cure HIV or AIDS is a little known fact. This gap of knowledge has two main reasons:

1. The pharmaceutical multinationals invest millions of Rand in organisations promoting ARVs – despite their inability to cure.
2. Moreover, hardly any of the patients taking ARV pills receives this product information – mandated by law – because in many doctor's offices and hospitals ARV pills are deliberately removed from the manufacturer's box containing the warning long before the patients receive the ARV pills.

The pharmaceutical multinationals support special organisations, which infiltrate the hospitals in the developing world under the veil of charity. A main function of these organisations is, to take the ARV pills out of the manufacturers box and “repackage” them in colourful daily supply boxes – removing any product information and warning notice.

One of these “repackaging” organisations is called “Médecins Sans Frontières”, MSF (Doctors Without Borders). The picture above is taken from an MSF brochure. It shows how ARV pills are “repackaged” from the original containers (upper right hand corner) into a patient box, which no longer contains the warning notice – but instead the colourful logo of MSF.


PHARMACEUTICAL COLONIALISM – CONVENTIONAL –



Over the past decades, pharmaceutical colonialism did not differ much from other forms of corporate colonialism. High priced products – in this case patented drugs – were exported from the manufacturing sites of multinational drug companies, generally located within leading industrialised nations, such as USA, UK, Germany and France.

Since the African people could not afford these drugs, the drug multinationals had to push the governments of Africa to use millions of Rand of taxpayers' money to pay for the mass import of these drugs.

PHARMACEUTICAL COLONIALISM – THE ‘ASPEN’ SCHEME –



As a result of increasing criticism of the pharmaceutical multinationals, they thought of new, cunning models of marketing their drugs across Africa. The pharmaceutical investment circles were the economic motors launching pharmaceutical manufacturing companies in South Africa, such as Aspen. The PR effect of ARV pills “manufactured in South Africa” was several fold. First, it decreased the negative publicity about open pharmaceutical colonialism. Second, the fact of an African production site for these drugs was used as a strategic advertising claim to expand the market for ARVs and other drugs across Africa. The economic benefits from the “Aspen Scheme” for the foreign drug investors surpassed all their expectations.


THE CONSEQUENCES OF THE ARV FRAUD FOR THIS LITIGATION

Considering these facts, it is of utmost concern that the SAMA functionaries and the TAC and their witnesses throughout their Application simply ignore these facts and rather allege the opposite to be true. In order to cover up the fact that ARV drugs have never been shown to prevent or cure HIV or AIDS, the SAMA functionaries and the TAC filed several witness statements by South African doctors. These doctors are apparently trying to blind the Court about the unproven efficacy of ARV drugs with the help of their academic titles and list of publications.

Of course, none of these doctors listed by the SAMA and the TAC as "witnesses" is able to change the scientific facts provided by the manufacturers of these drugs themselves. Moreover, these experts now need to be held responsible for making false and misleading statements to the public about unproven health benefits of ARVs.

Thus, most of the witnesses listed by SAMA and the TAC as "experts" on ARVs have in common that

1. they are economically or academically dependent on the pharmaceutical business with patented ARV drugs,
2. they try to impress the High Court with ARV-promoting publications published in journals or presented at conferences supported by the pharmaceutical industry,
3. they do not have any scientific record in the area of micronutrient research or nutritional therapies, while – at the same time – allowing themselves to cast false judgements even on the most basic facts of biological sciences,
4. with their statements to the Court these witnesses try to establish ARV drugs as the only scientifically proven therapy for AIDS,



5. with their witness statements openly contradict the official product information by the manufacturers of these drugs that they can neither treat HIV nor AIDS.

By presenting these obviously false facts in this Application these doctors have been identified as “pseudo-experts” and have disqualified themselves as credible witnesses. The key facts of their statements about ARVs are evidently false and their affidavits can no longer be considered relevant.

THE PHARMACEUTICAL INDUSTRY'S APPROACH TO AIDS AS A GLOBAL MARKET

In the following paragraphs I address the business strategy behind the promotion of toxic ARVs – as AIDS chemotherapy – by the pharmaceutical industry. In brief, the pharmaceutical response to AIDS is to treat this epidemic as a global market and a multibillion Rand opportunity to increase its return on investments in patented ARV drugs.

ARVs are the most common pharmaceutical approaches to AIDS. Most ARVs are derivatives of drugs used in the “chemotherapy” of cancer. The underlying therapeutic mechanism of these drugs is to damage or destroy the cells of the body in the hope to also impair or destroy cancer cells or – in the case of AIDS – virus containing cells.

It is basic knowledge that the primary target organ of these toxic chemotherapeutic drugs is the bone marrow in the human body. Moreover, the first cells toxically damaged are the fastest reproducing cells, i.e. the blood cells deriving from the bone marrow. This inevitably leads to the impaired production and function of almost all subtypes of white blood cells and other cells that determine immune function in the body.

AIDS, the acquired immune deficiency syndrome, is by definition an immune deficiency condition – i.e. a disease characterised by an impaired function of the immune system. A 13-year old understands that a toxic agent that damages the immune cells cannot cause the immune system to improve and correct immune deficiencies – rather than achieving the opposite – further aggravating this condition.


Over the past two decades the AIDS epidemic has become a multibillion Rand market for the pharmaceutical investment industry with ARVs being essentially supplied from three drug exporting countries, the US, the UK and Germany.

The continued growth and expansion of the global ARV market is essentially achieved by responding to the epidemic of immune deficiencies with the promotion of chemotherapeutic drugs – ARVs – that aggravate immune deficiencies. Through this marketing strategy, existing markets for ARVs and other drugs are being continuously expanded and markets for newly generated diseases are constantly being created.

This aggressive marketing strategy exposes patients taking ARV drugs to compromise their immune systems and becoming susceptible to tuberculosis and other bacterial, viral and fungal disease. Even leprosy increases among patients taking ARV drugs, a fact that has not only alerted the scientific community, but the public at large as documented by a recent article in the “New York Times.”*

The New York Times

October 24, 2006



“Worrisome Link: AIDS Drugs and Leprosy”

“... Dr Gilla Kaplan, a professor at the University of Medicine and Dentistry of New Jersey and one of the first to study connections between AIDS and leprosy, agreed. Antiretroviral treatment, she said, “is going to flush out the silent leprosy by making it symptomatic...”

PHARMACEUTICAL COLONIALISM AND AIDS

Step-wise Drug Marketing Scheme by Pharmaceutical Stakeholders

I and II are key steps to launch the drug marketing spiral

I Under the false pretext describing ARVs as a cure for AIDS, drug companies and their stake holders in medicine and media are pushing to test every South African for HIV tests.

II These lobbyists of drug multinationals pressure tens of thousands of HIV infected South Africans – even without any signs of AIDS – **to take highly toxic ARV drugs**

While ARV drugs can neither cure HIV nor AIDS, they in fact destroy the immune system and cause inflammation, organ damage and other side effects – **creating the market for even more drug sales.**

ARV drugs weaken the immune system of everyone. These drugs do not prevent immune deficiencies, but in fact cause them and render the body susceptible to fungal and other common infections – **creating the market for even more drug sales.**


The continued intake of ARVs weakens the immune system so much that severe infectious diseases, including tuberculosis, leprosy and others, appear and also spread in epidemic proportions – **creating the market for even more drug sales.**

The mass supply of chemical drugs cause ever new and even more aggressive strains of micro-organisms appear – **creating the market for even more sales of drugs and new “drug combinations”.**


Consequences for People and Governments:

Millions of People Die

National Economies Drained



The AIDS-Epidemic is the door opener for the pharmaceutical investment business and its political stakeholders to keep Africa – and the entire developing world – in a stranglehold. Their strategic goal: Create new diseases as new multi-billion rand markets for their patented drugs that drain the national economies.



Particularly alarming are the toxic side effects of so-called highly active anti-retroviral treatments (HAART) which have been accompanied by an increase in deaths attributable to cancer, especially lung cancer.* For more detailed information about the adverse effects of ARVs I refer the honourable Court to the affidavit of the sixth Respondent.


The accusation that the pharmaceutical industry responds to diseases by promoting drugs that do not cure these diseases, rather than further aggravating them, is serious and is not made easily. One may even reject such a serious accusation for the simple fact that it violates all ethical standards as well as national and international laws. The fact is, however, that such marketing schemes by the pharmaceutical industry are widely used and are in no way limited only to ARV drugs and the AIDS epidemic.

For more than a half a century chemotherapeutic agents have been promoted by drug companies as a “treatment of choice” in the fight against cancer. The ineffectiveness of chemotherapy in the global fight against cancer is evidenced by the fact that until today cancer has remained the third leading cause of death in the industrialised world. While this failure has been highly publicised, the reasons for it have not. Hardly anyone knows that many chemotherapeutic agents promoted by drug companies as cancer “treatments” are actually well-established “human carcinogens”, as documented by the Merck Manual and the official US-“Report on Carcinogens.” These carcinogens include such widespread cancer agents as Cyclophosphamide, Tamoxifen, Melphalan and others.*

The pharmaceutical marketing scheme to sell drugs that are known to cause cancer to millions of cancer patients –, and to promote drugs that are known to damage the immune system of millions of AIDS patients – is rather daring. This marketing scheme only works under one condition: that both cancer and AIDS are being upheld as “untreatable” and essentially “death verdicts.”

This sobering scientific analysis has far-reaching economic consequences. Should those millions of patients affected by cancer or

How The Pharmaceutical Industry Promotes Epidemics As Global Drug Markets



The pharmaceutical industry lives from expanding disease markets

The marketing of ARV drugs to immune deficient AIDS patients is a mere copy of the marketing scheme used by drug multinationals for decades to profit from the global cancer epidemic.

- **Cancer:** Toxic chemical drugs are being promoted to millions of cancer patients with the false promise to expand or even save their lives. Yet, the most frequent side effects of these chemical drugs is damage to millions of cells and the triggering of new cancer – which further increase drug sales.
- **AIDS:** In a similar way, toxic chemical drugs (ARVs) are being promoted to millions of AIDS patients with the false promise to cure or save their lives. However, the scientific facts about these drugs are different: They destroy the immune system, cause more immune deficiency and thereby pave the way for the development of many other infectious diseases, including tuberculosis and other bacterial, viral and fungal diseases. These diseases, too, are multi-billion Rand drug markets.

those affected by AIDS ever learn that science-based and safe health approaches are available to effectively help control these diseases, the global market of chemotherapeutic drugs will inevitably collapse.

THE FAR-REACHING CONSEQUENCES OF THE PHARMACEUTICAL BUSINESS WITH THE AIDS EPIDEMIC

It goes without saying that the pharmaceutical investment interests are trying to do everything to keep the multibillion Rand investment market with patented ARV drugs alive. Worse, as an investment industry they do everything to expand this ARV drug market – i.e. to expand the AIDS epidemic under the pretext of fighting it.

The marketing strategy behind this pharmaceutical approach to AIDS as well as the devastating global consequences are well documented, but little known: The World Health organisation (WHO) defined AIDS in an official conference in Bangui, Central Africa, as the occurrence of five typical “AIDS-defining symptoms.” They are: fever, diarrhoea, persistent cough, weight loss and TB symptoms.

To expand their global markets with AIDS drugs, the pharmaceutical industry has consistently tried to reduce the problem of AIDS to a simple equation, the infection with the human immunodeficiency virus (HIV). It is currently vigorously debated whether the pharmaceutical equation $HIV=AIDS$ is a scientific fact or a marketing strategy for the promotion of ARV drugs.


The answer to this question is surprisingly simple and comes from WHO data as recently as 2001.* The statistical evaluation of these unique global data show that:

- From all people infected with HIV statistically less than 20 % develop the immune deficiency condition AIDS – even after 13 years.
- This means that after more than a decade over 80% of all HIV-infected individuals remain AIDS free.
- If HIV were the highly pathogenic micro-organism that it is being promoted to be by pharmaceutical medicine, AIDS-symptoms would occur in about 100% of the cases – and within a relatively short time.
- While HIV may be present in AIDS patients it cannot be the only cause of AIDS.

On the other hand, the statistical evaluation of large scale clinical studies using ARV drugs in HIV-positive patients show a distinctly different picture:*

HIV IS NOT THE ONLY CAUSE OF AIDS

– Based on Global Data* –




An analysis of worldwide data from AIDS patients, published by the World Health Organisation (WHO), shows that within a period of thirteen years, less than 20 % of HIV positive people develop AIDS.

These data clearly show that HIV cannot be the general or only cause of AIDS, otherwise every HIV infection would automatically cause AIDS.

Moreover, if more than 80 % of HIV-infected people are still alive after thirteen years – even without taking ARVs – HIV cannot be the aggressive virus that necessarily kills people within months or a few years. These WHO data do not exclude that HIV can contribute to AIDS, but it cannot be its sole cause.

ARV INTAKE EVENTUALLY CAUSES AIDS

– Based on ARV drug studies** –



In sharp contrast, the evaluation of two of the largest clinical studies in which AIDS patients took ARV drugs show, that almost all people taking ARV drugs eventually develop AIDS and die at a high rate. It can be calculated that all patients taking ARVs would develop full blown AIDS and die from it in less than thirteen years.

The pharmaceutical industry knows these facts. Thus, they have an interest to artificially create the equation "HIV = AIDS = Death". For it is only with this equation that they can justify the promotion of toxic and ineffective drugs to HIV-infected people – even without any signs of the AIDS disease.

The above data also show that the drug companies have an incentive to promote ARV drugs, because they obviously expand the AIDS epidemic and thereby the multi-billion Rand drug market.

- The death rate from AIDS among HIV-positive patients taking ARVs is statistically at least 7 % each year.
- This means that almost 100 % of those patients taking toxic ARVs have developed AIDS and have died after 13 years.

Several important conclusions can be drawn from these facts which are summarised in the attached graph:*

- 1. While the majority of HIV-positive patients not taking ARVs have an 80 % chance to survive 13 years AIDS free, the statistical chances to survive this period for patients taking ARVs are close to zero.**
- 2. The promotion of ARV drugs to all HIV positive patients is not based on scientific facts nor does it help the patients. It is solely built on marketing strategies of pharmaceutical companies selling ARVs and looking to expand their drug markets.**
- 3. The only way to cause AIDS symptoms in about 100 % of HIV infected people is to promote toxic ARVs to them – immediately after they have been diagnosed as HIV positive.**

Considering these facts the need for effective, safe and affordable alternatives is paramount. Even if they are not cures for HIV either, the minimum they can accomplish is to strengthen the immune system of patients affected by immune deficiencies / AIDS – and not aggravate these conditions.

The promoters of the ARV drug business argue that natural vitamins and nutritional medicine endanger the lives of AIDS patients.

The facts on the following pages correct this myth.